Respiratory Drugs Market Size

Global Respiratory Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.01 billion in 2024 to USD 7.71 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032). 

The demand for respiratory drugs is primarily being boosted by the increasing prevalence of respiratory disorders around the globe. Additionally, increasing air pollution and exposure to allergens and growing awareness regarding respiratory diseases leading to an increase in diagnosis and treatment are some of the key factors, which are contributing to the growth of the respiratory drugs market during the forecast period from 2025 to 2032.

In high-income countries, tobacco smoking is responsible for more than 70% of COPD cases. In contrast, in low- and middle-income countries (LMICs), tobacco smoking contributes to 30–40% of COPD cases, with household air pollution being a significant risk factor.

Tobacco smoking is a significant contributor to respiratory disorders like COPD, lung cancer, and respiratory infections. When people smoke, they inhale harmful substances into their lungs, causing damage over time. COPD, which includes conditions like chronic bronchitis and emphysema, is ubiquitous among smokers because tobacco smoke irritates and inflames the airways, making it hard to breathe.

Is AI Breathing New Life into the Respiratory Drugs Market?

Artificial intelligence (AI) is significantly transforming the market in 2024, and operates innovation in drug discovery, clinical studies, patient care and market growth. AI-operated platforms accelerate the identification and adaptation of drug candidates by analyzing a large-scale data set to predict molecular behavior, disease patterns and treatment efficiency. Pharmaceutical companies such as Amneal and Moderna benefit from these opportunities to reduce research time and costs, which accelerates the development of new respiratory tracts. In addition, AI clinical studies increase by identifying appropriate patient colleagues and enabling real-time adjustment through data analysis. Collaboration such as Astrazneca and Artiq shows how AI equipment can monitor the lung function at a distance, making the tests more effective and adapting to the patient.

On the patient care front, AI is enabling highly personalized treatment plans. Platforms such as Diag-Nose.io’s RhinoMAP use patient-specific data like genetic markers and environmental triggers to recommend the most effective medications, aiming for symptom-free outcomes in conditions like asthma and COPD. Moreover, smart inhalers and AI-integrated wearable devices are improving drug adherence and early detection of exacerbations. Tools like Respira Labs’ Sylvee use acoustic analysis to assess lung function in real-time, supporting proactive management of respiratory conditions.